Wells Fargo analyst Jacob Hughes lowered the firm’s price target on Karuna Therapeutics to $257 from $262 on higher Opex, while keeping an Overweight rating on the shares. The firm notes pipeline timelines are on track, with EMERGENT-3 top-line data readout in March.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KRTX:
- Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25)
- Karuna Therapeutics signing exclusive global license agreement for TRPC4/5
- Karuna Therapeutics appoints William Kane as Chief Commercial Officer
- Karuna Therapeutics initiated with a Neutral at UBS
- Karuna Therapeutics initiated with an Overweight at Piper Sandler
